The Bcr ± Abl tyrosine kinase is responsible for the oncogenic phenotype observed in Philadelphia chromosome-positive leukemia and induces resistance to apoptotic cell death in a variety of cell types. Recent evidence supports the hypothesis that these two properties of Bcr ± Abl are derived from cooperative but distinct signaling pathways. Phosphatidylinositol 3-kinase (PI3K), which has been suggested to associate with and become activated by Bcr ± Abl, has been shown to be required for Bcr ± Abl-mediated cell growth. Also, PI3K has been implicated in resistance to apoptosis induced by some growth factors. We therefore examined the role of PI 3-kinase in the anti-apoptotic effect of Bcr ± Abl. First, we confirmed that expression of p185 bcr ± abl in HL-60 cells, which renders these cells resistant to apoptosis, induces tyrosine phosphorylation of the p85 subunit of PI3K. Consistent with this result, we observed a 20-fold increase in PI3K activity upon immunoprecipitation of tyrosinephosphorylated proteins from cells expressing Bcr ± Abl versus control cells. Nevertheless, treatment of HL-60.p185
Introduction
The Bcr ± Abl tyrosine kinase found in Philadelphia chromosome (Ph 1 )-positive leukemia occurs in two different forms depending on the breakpoint of the Bcr gene on chromosome 22. In chronic myelogenous leukemia (CML), a 210 kDa Bcr ± Abl protein is associated with the proliferation and accumulation of myeloid cells and their precursors (Shtivelman et al, 1985) , whereas a 185 kDa form of this protein is responsible for the pathogenesis observed in Ph 1 -positive acute lymphocytic leukemia (ALL) (Clark et al, 1988) . Both forms of Bcr ± Abl proteins are able to recapitulate a CML-like disease in mice (Daley et al, 1990; Elefanty et al, 1990; Gishizky et al, 1993; Kelliher et al, 1990) .
It has been demonstrated that Bcr ± Abl not only induces transformation of fibroblasts and hematopoietic cells (Lugo et al, 1990; McLaughlin et al, 1989) but also confers resistance to a variety of apoptosis-inducing agents (Bedi et al, 1994; Laneuville et al, 1994; McGahon et al, 1994 Smetsers et al, 1994) . The CML cell line, K562, was shown to be resistant to CD95-mediated apoptosis , as well as apoptosis induced by actinomycin D, camptothecin, etoposide and cycloheximide (McGahon et al, 1994) . Down-regulation of Bcr ± Abl by antisense oligonucleotides abolishes the resistance of K562 cells to these insults (McGahon et al, 1994 and induces apoptosis in another Ph 1 -positive cell line, BV173 (Smetsers et al, 1994) . In addition, ectopic expression of Bcr ± Abl renders BaF3 and 32D cells interleukin 3 (IL-3) independent (Cortez et al, 1995; Daley et al, 1992) , such that they no longer undergo apoptosis upon IL-3 withdrawal.
Many proteins have been shown to associate directly or indirectly with Bcr ± Abl. Among such proteins are the regulatory transcription factors c-Myc (Afar et al, 1994; Sawyers et al, 1992) and c-Myb (Ratajczak et al, 1992) , the adapter molecules Shc (Puil et al, 1994) , Grb-2 (Pendergast et al, 1993) , and Crkl (de Jong et al, 1995; ten Hoeve et al, 1994) , p21
ras (Goga et al, 1995; Mandanas et al, 1993; Pendergast et al, 1993) , p120 ras-gap , p160
bcr (Lu et al, 1993 ), c-Cbl (de Jong et al, 1995 , and PI3K (Gotoh et al, 1994; Skorski et al, 1995; Varticovski et al, 1991) . These molecules represent potential substrates for the Bcr ± Abl tyrosine kinase and are likely to be important in determining the transformation or the apoptosis-resistant phenotypes, or both.
PI3K is a heterodimeric molecule composed of an adapter subunit of 85 kDa (p85) which couples the catalytic 110 kDa subunit (p110) to activated protein tyrosine kinases (Carpenter et al, 1993; Parker and Waterfield, 1992) . Two isoforms of p85, a and b, have been isolated (Otsu et al, 1991; Volinia et al, 1992 ) each containing one SH3 and two SH2 domains. Interestingly, sequence homology analysis identified another domain in p85 with significant similarity to the Bcr gene (Otsu et al, 1991) , which suggests that it may possess GAP activity. PI3K is a bifunctional kinase that expresses lipid kinase activity that phosphorylates the D-3 position of the inositol ring of phosphatidylinositol, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-biphosphate and also protein serine kinase activity towards its p85 subunit .
The 3'-phosphorylated inositides produced upon activation of PI3K are thought to act as second messenger molecules, however, the exact role of this enzyme in signal transduction is yet to be elucidated. PI3K is found associated with growth factor receptors and can be activated by protein tyrosine kinases in a variety of cell types (Panayotou and Waterfiel, 1993) . It has also been found complexed with the polyoma middle T antigen/ pp60 c-src transforming complex (Ling et al, 1992) and with the activated PDGF receptor (Coughlin et al, 1989; Fantl et al, 1992; Valius and Kazlauskas, 1993) suggesting a role in mitogenesis and cell transformation. Most importantly, PI3K was shown to be required for both NGF-and PDGFmediated protection from apoptosis in PC-12 neuronal cells (Yao and Cooper, 1995) . It was also demonstrated that the PI3K requirement for anti-apoptotic effect depends upon the survival factor used (Minshall et al, 1996) . Both IL-3 and IGF-1 stimulate PI3K activity in IL-3-dependent FDCP/Mac-1 murine hematopoietic progenitor cells. Down-regulation of PI3K by wortmannin abrogates IGF-1-mediated inhibition of apoptosis in these cells, but does not interfere with the antiapoptotic effect of IL-3 (Minshall et al, 1996) . Varticovski et al. (1991) detected elevated levels of PI3K activity in cells that expressed transforming variants of abl, and provided evidence that this was due to an association of oncogenic Abl and PI3K. Similarly, others have observed association of Bcr ± Abl and PI3K as well as tyrosine phosphorylation of the latter in p185 bcr ± abl -expressing cells (Gotoh et al, 1994) . Furthermore, PI3K activity was suggested to be regulated by Bcr ± Abl tyrosine kinase and required for the growth of Bcr ± Abl-expressing cells, based on the ability of wortmannin and p85a antisense oligonucleotides to inhibit growth of these cells (Skorski et al, 1995) . In addition, in p210 bcr ± abl -positive hematopoietic cells, PI3K was found to associate with the adapter protein Shc (Harrison Findik et al, 1995) , which seems to provide an alternative signal from Bcr ± Abl to Ras activation (Goga et al, 1995) , and the latter has been suggested to participate in Bcr ± Abl-induced resistance to apoptosis (Cortez et al, 1995; Sakai et al, 1994) . These observations led us to investigate the possible role of PI3K in Bcr ± Ablmediated resistance to apoptosis.
Results

Bcr ± Abl triggers PI3K tyrosine phosphorylation in HL-60 cells
Infection of HL-60 cells with a retrovirus containing p185 bcr ± abl renders these cells resistant to a variety of apoptosis-inducing agents (Amarante-Mendes et al, submitted). We used this system to address whether PI3K is involved in Bcr ± Abl-mediated resistance to apoptosis. First, we observed that similar amount of the p85 subunit of PI3K could be immunoprecipitated from Bcr ± Abl-positive and negative HL60 cells ( Figure 1A ). Second, ectopic expression of Bcr ± Abl in HL-60 cells induced an intense tyrosine phosphorylation of the p85 subunit of PI3K and of other substrates ( Figure 1B ). Anti-Ptyr immunoprecipitation of Bcr ± Abl-expressing HL-60 cells revealed a 20-fold increase of lipid kinase activity in the precipitated fraction when compared to Bcr ± Abl negative counterparts ( Figure 1C ), confirming the phosphorylation state of the PI3K molecule. These results are similar to those reported by others (Gotoh et al, 1994; Varticovski et al, 1991) .
Inhibition of PI3K activity does not impair the antiapoptotic effect of Bcr ± Abl Since PI3K activity seems to be involved in the growth of Bcr ± Abl-expressing cells (Skorski et al, 1995) and in the PDGF-, NGF-and IGF-1-mediated resistance to apoptosis (Minshall et al, 1996; Yao and Cooper, 1995; Kulik et al, 1997) , we investigated whether this enzyme plays a role in the ability of Bcr ± Abl to inhibit apoptosis. Treatment of HL-60 and HL-60.p185
bcr ± abl cells with wortmannin substantially decreased the activity of PI3K in both cell lines, in a dosedependent manner (Figure 2A ). This effect was detected in anti-p85 IPs obtained immediately after the 45 min-incubation with wortmannin ( Figure 2A and B) and persisted during the 5 h-treatment of the cells with the apoptosis-inducing drugs ( Figure 2B ). However, this drug had no effect on the ability of Bcr ± Abl to confer resistance to either VP-16-or CHX-induced apoptosis, in a 5 h assay (Figure 3 ). This was true even at very high doses of wortmannin, such as 100 mM (Figure 4) . It is important to note that wortmannin was shown to block IGF-1-mediated resistance to apoptosis in a 15 h assay (Kulik et al, 1997) , indicating that regardless of the short half-life of wortmannin, this drug is able to drive a potent and long-lasting interference with the anti-apoptotic signaling of IGF-1. These data indicate that PI3K activity is not required for Bcr ± Ablmediated resistance to apoptosis in HL-60 cells.
To rule out the possibility that these results were particular to HL-60 cells, two other cell lines were treated with wortmannin and tested for resistance to apoptosis. K562 cells were previously shown to be relatively resistant to a variety of apoptosis-inducing agents and this phenotype could be reverted by treatment with antisense oligonucleotides directed against c-abl (McGahon et al,  1994 ). BaF3.Bcr ± Abl cells were also shown to be resistant to IL-3 withdrawal and g-irradiation-induced apoptosis (Cortez et al, 1995) . Similarly to our results with HL-60 cells, wortmannin induced a marked decrease in PI3K activity in these two cell lines ( Figure 5A ). Again, inhibition of PI3K activity in K562 and BaF3.Bcr ± Abl cells did not interfere with the level of apoptosis observed in these cells ( Figure 5B ). K562 cells showed a strong resistance to staurosporine and CHX but only a partial protection against 100 mM VP-16. Even in this latter case, where a high enough concentration of VP-16 did induce some cell death, down regulation of PI3K did not amplified the apoptotic effect of the drug.
Discussion
In this paper we have shown that Bcr ± Abl induces tyrosine phosphorylation of the p85 subunit of PI3K in HL60 cells, which suggested a possible role for downstream events in Bcr ± Abl-mediated oncogenesis. Nevertheless, inhibition of PI3K activity by treatment with wortmannin did not interfere with the apoptosis-resistant phenotype observed in the Bcr ± Abl-positive HL-60, K562 and BaF3 cells. PI3K activity was found to be required for the antiapoptotic effect mediated by NGF, PDGF and IGF-1, but not IL-3 (Minshall et al, 1996; Yao and Cooper, 1995; Kulik et al, 1997) . Given the fact that wortmannin inhibits PI3K activity without interfering with Bcr ± Abl-mediated resistance to apoptosis, we propose that the Bcr ± Abl antiapoptotic signaling is independent from the 3'-phosphorylated inositides produced upon activation of PI3K. It is possible that PI3K molecules participate in the antiapoptotic signaling through a non-enzymatic way. The tyrosine phosphorylation of its p85 subunit may specifically direct a different set of substrates to the signaling cascade triggered by Bcr ± Abl. Since p85 PI3K is composed of one SH3 and two SH2 domains, it can act as an adapter protein. In this case, tyrosine phosphorylation in specific sites within one or more domains may not change PI3K enzymatic activity but rather direct the molecule to a particular sub-cellular localization where it will interact with different substrates. In this regard, it was shown that the SH2 domain of p85 PI3K binds to tyrosine-phosphorylated SHC in p210 bcr ± abl -expressing cells (Harrison Findik et al, 1995) which was shown to provide an alternative signal from Bcr ± Abl to Ras activation (Goga et al, 1995) , and the latter has been suggested to participate in Bcr ± Ablinduced resistance to apoptosis (Cortez et al, 1995; Sakai et al, 1994). More recently, Griffin and collaborators, using co-immunoprecipitation and Far-Western blotting approaches, suggested that PI3K binds primarily to p120 cbl in Bcr ± Abl-expressing cells and that Cbl associates both directly with Bcr ± Abl and indirectly via the interaction with CRKL or c-CRK (Sattler et al, 1996) . Varticovski et al. (1991) found a direct correlation between the ability of Abl variants to transform cells and to increase cellular levels of PIP 3 , which strongly suggests that PI3K activity is important in Abl-mediated transformation. Similarly, others have suggested that PI3K is involved in Bcr-Abl-mediated cell growth (Skorski et al, 1995) . At least 20 times more PI3K was found tyrosine phosphorylated in Bcr ± Abl-expressing HL-60 cells compared to control cells, as detected by the lipid kinase assay in anti-Ptyr IPs (Figure 1B) , confirming the participation of PI3K in down stream events initiated by Bcr ± Abl in HL-60 cells. Since we did not observed any participation of PI3K activity in Bcr ± Abl-mediated resistance to apoptosis, it is reasonable to propose that Bcr ± Abl triggers two related events in the pathology of Ph 1 -positive leukemia, namely cellular transformation and resistance to apoptosis, by biochemically distinct signaling pathways. It has been shown that Bcr ± Abl can indeed trigger multiple alternative signals depending on the cell type (Cortez et al, 1995; Goga et al, 1995) . Pendergast and colleagues (Cortez et al, 1995) showed that the IL-3-dependent cell line 32D was rescued from IL-3 deprivation-or g-irradiation-induced apoptosis by expressing a mutant Bcr ± Abl (D 176 ± 427) that has an impaired transforming ability in these cells. Thus, Bcr ± Abl-induced resistance to apoptosis can occur independently of cellular transformation.
Whether the anti-apoptotic effect or the transforming ability of Bcr ± Abl, or a combination of both, are responsible for the myeloid expansion culminating in the blast crisis observed in CML patients remains to be determined. Understanding the molecular mechanisms by which Bcr ± Abl generates its anti-apoptotic state will provide insights into the apoptotic machinery of the cell as well as help the development of new strategies for therapy of Ph1-positive leukemias.
Materials and Methods
Cell culture and reagents bcr ± abl cells were obtained by retroviral transfection with pSRaMSVp185 bcr ± abl tkneo and described elsewhere (AmaranteMendes et al, submitted). K562 cells were obtained from ATCC, BaF3 and BaF3.p185 bcr ± abl were kindly provided by Dr. Ann Marie Pendergast.
Etoposide (VP-16, Sigma), staurosporine (Sigma) and wortmannin (Sigma) were prepared as 100 mM, 1 mM and 10 mM stock solutions in DMSO, respectively. Cycloheximide (Sigma) was prepared in ethanol as a 50 mM stock solution.
Wortmannin treatment
Cells were washed three times in HBSS and resuspended in serumfree RPMI-1640, containing different concentrations of wortmannin (1610 7 cells in 0.5 ml). After 45 min at 378C, suspensions were diluted with RPMI-FCS to 1610 6 cells ml 71 and then incubated with VP-16 or CHX for 5 h. At this point, additional wortmannin was added to maintain the same concentration. Activity of PI3K in the treated cells was determined in kinase assays on anti-p85 IPs.
Immunoprecipitations and Westernimmunoblotting
A total of 1610 7 cells were washed twice in PBS and solubilized in 0.5 ml of lysis buffer (20 mM Tris-Cl pH 7.4; 150 mM NaCl; 1% NP-40; 100 mg ml 71 soybean trypsin inhibitor; 10 mg ml 71 each leupeptin and aprotinin; 1 mM PMSF; 1 mM NaVO 4 ; 5 mM EDTA). Lysates were pre-cleared with protein G-agarose beads (Pharmacia) and immuno- precipitated with either NRS, rabbit anti-p85 PI3K pAb (UBI, Lake Placid, NY), mouse anti-Bcr mAb (G6; Santa Cruz Laboratories) or mouse anti-phosphotyrosine (PTyr) pAb (4G10). Immunoprecipitates were resolved in 6% SDS ± PAGE gels and transferred to PVDF membranes (Millipore). Filters were probed with suitable primary antibodies and the reactions were detected with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit Ab using an enhanced chemiluminescence system (ECL, Amersham)
PI3K assay
In vitro PI3K assays were performed as previously described (Fukui and Hanafusa, 1989; Von Willebrand et al, 1996) . Briefly, immunoprecipitates were washed extensively to remove NP-40, and lipid kinase activity was assessed using [g 32 P]ATP and phosphatidylinositol as substrate. Reaction products were separated by thin-layer chromatography on silica-gel plates and detected by autoradiography. Relevant spots were quantitated by Cerenkov counting.
Determination of apoptosis
DNA fragmentation was estimated by cell cycle analysis of total DNA content as described elsewhere (Nicoletti et al, 1991) , with slight modifications. A total of 2610 5 cells were washed twice in PBS and resuspended in 0.5 ml of hypotonic fluorochrome solution (50 mg ml 71 propidium iodide and 0.1% Triton X-100 in 0.1% sodium citrate). After 30 min at 48C in the dark, the fluorescence of individual nuclei was measured using a FACScan flow cytometer (BectonDickinson, Mountain View, CA). The percentage of hypodiploid nuclei correlates with the extent of apoptosis in the sample.
The percentage of cell death was determined by analyzing changes in the light scattering properties due to reduction in cell size and increase in granularity, as well as permeability to propidium iodide (Martin et al, 1994; .
